Liu ZT - Search Results

1

Comprehensive analysis of the transcription factor CREB3L4/RASEF signaling axis in lung adenocarcinoma: implications for pathogenesis and therapeutic strategies.

Liu X, Guo L, Chen X, Liu ZT, Zhu YH, Xiao M, Liu JZ, Chen X, Zhang YL. Liu X, et al. Among authors: liu zt. Am J Transl Res. 2024 Nov 15;16(11):6399-6422. doi: 10.62347/JAHC2715. eCollection 2024. Am J Transl Res. 2024. PMID: 39678581 Free PMC article.

2

Development and validation of an immune-related gene prognostic index for lung adenocarcinoma.

Liu Z, Lei Y, Shen J, Zhao G, Wang X, Wang Y, Kudo Y, Liao J, Huang Y, Yu T. Liu Z, et al. J Thorac Dis. 2023 Nov 30;15(11):6205-6227. doi: 10.21037/jtd-23-1374. Epub 2023 Nov 24. J Thorac Dis. 2023. PMID: 38090291 Free PMC article.

3

Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma.

Liu ZT, Shen JT, Lei YJ, Huang YC, Zhao GQ, Zheng CH, Wang X, Wang YT, Chen L, Li ZX, Li SZ, Liao J, Yu TD. Liu ZT, et al. BMC Cancer. 2023 Nov 24;23(1):1141. doi: 10.1186/s12885-023-11579-7. BMC Cancer. 2023. PMID: 38001428 Free PMC article.

4

Comprehensive Analysis of Cellular Senescence-Related Genes in Prognosis, Molecular Characterization and Immunotherapy of Hepatocellular Carcinoma.

Sun L, Liu Z, Ning K, Wu Z, Chen Z, Wu Z, Yin X. Sun L, et al. Biol Proced Online. 2022 Dec 19;24(1):24. doi: 10.1186/s12575-022-00187-7. Biol Proced Online. 2022. PMID: 36536279 Free PMC article.

5

Chemokine‑ and chemokine receptor-based subtypes predict prognosis, immunotherapy and chemotherapy response in colorectal cancer patients.

Zhu W, Zhao S, Cheng X, Wu C, Liu Z, Huang J. Zhu W, et al. Int Immunopharmacol. 2024 Jun 15;134:112172. doi: 10.1016/j.intimp.2024.112172. Epub 2024 May 3. Int Immunopharmacol. 2024. PMID: 38703566

6

Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.

Peng X, Zhu J, Liu S, Luo C, Wu X, Liu Z, Li Y, Yuan R. Peng X, et al. Front Immunol. 2022 Sep 28;13:990790. doi: 10.3389/fimmu.2022.990790. eCollection 2022. Front Immunol. 2022. PMID: 36248822 Free PMC article.

7

SULF1 regulates malignant progression of colorectal cancer by modulating ARSH via FAK/PI3K/AKT/mTOR signaling.

Zhu W, Wu C, Liu Z, Zhao S, Cheng X, Huang J. Zhu W, et al. Cancer Cell Int. 2024 Jun 6;24(1):201. doi: 10.1186/s12935-024-03383-5. Cancer Cell Int. 2024. PMID: 38844922 Free PMC article.

8

OTU deubiquitinase, ubiquitin aldehyde binding 2 (OTUB2) modulates the stemness feature, chemoresistance, and epithelial-mesenchymal transition of colon cancer via regulating GINS complex subunit 1 (GINS1) expression.

Zhu W, Wu C, Liu Z, Zhao S, Huang J. Zhu W, et al. Cell Commun Signal. 2024 Aug 29;22(1):420. doi: 10.1186/s12964-024-01789-2. Cell Commun Signal. 2024. PMID: 39210373 Free PMC article.

9

Molecular subtype identification and signature construction based on Golgi apparatus-related genes for better prediction prognosis and immunotherapy response in hepatocellular carcinoma.

Sun L, Liu Z, Wu Z, Ning K, Hu J, Chen Z, Wu Z, Yin X. Sun L, et al. Front Immunol. 2023 Mar 27;14:1113455. doi: 10.3389/fimmu.2023.1113455. eCollection 2023. Front Immunol. 2023. PMID: 37051238 Free PMC article.

10

Identification of LncRNA Prognostic Signature Associated With Genomic Instability in Pancreatic Adenocarcinoma.

Zhu J, Huang Q, Peng X, Luo C, Liu S, Liu Z, Wu X, Luo H. Zhu J, et al. Front Oncol. 2022 Mar 29;12:799475. doi: 10.3389/fonc.2022.799475. eCollection 2022. Front Oncol. 2022. PMID: 35433487 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

292 results

Search Page

Filters